Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Dr Reddy Laboratories

    Jump to

    • Dr Reddy’s denies report of cutting workforce costs by 25%, calls in 'factually incorrect'

      Business Standard had reported that several senior executives have been asked to resign amid Revlimid-linked margin strain, a claim that has been denied by the company.

    • CLSA selects Apollo Hospitals as top pick, says India's pharma set to outpace US growth

      The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially impacting companies like Dr Reddy's Laboratories, Zydus, and Cipla.

    • Dr Reddy's Q2 results: Net profit falls 15% to Rs 1,255 crore

      Dr Reddy's Q2 results: Revenue rises 17% to Rs 8,106 crore

    • Why everyone is not convinced about Dr Reddy’s latest acquisition

      Dr Reddy’s will have to invest significantly to improve growth rates of the acquired brands in nicotine replacement therapy

    • Nestle India, Dr Reddy's to form JV for nutraceutical brands in India, other agreed territories

      A joint press release from the companies said the partnership will bring together the well-known global range of nutritional health solutions as well as vitamins, minerals, herbals and supplements of Nestle Health Science (NHSc) with the strong and established commercial strengths of Dr Reddy's in India.

    • Pharma Sector set for gains: Dr Reddy's Lab sees significant long position build-up

      Pharma sector to be in focus this week in F&O segment with strong long build up witnessed in stocks like Zydus Life, Lupin, Lauruslabs, Divislab, and Dr. Reddy's.

    • Torrent Pharma acquires four brands from Dr Reddy’s Lab

    • Dr Reddy’s Q2 Results Preview: Revenue expected to increase 4-5%, PAT to decline 15%

    • Dr Reddy's looks to cut greenhouse gas emissions by 55 percent in 10 years

    • Dr Reddy's Labs sells rights of cloderm cream to EPI Health LLC

    • Dr Reddy's arm sells specialty skin cream Cloderm to EPI Health

    • Markets@Moneycontrol: Nifty likely to open higher; top 3 stocks which could give 7-9% return

    • Dr.Reddys bullish about better sales in Europe in FY19

    • Dr Reddy's recalls over 80,000 bottles of Atorvastatin from US

    • New draft pharma policy will reduce risks like generalisation of mkt: JM Financial

    • Dr Reddy's likely to divest Penicillin assets in US: Sources

    • US law firm files class action lawsuit against Dr Reddy's for misleading statements

    • Hold Dr Reddy's Laboratories; target of Rs 2450: Axis Direct

    • What's In A Name? Registration of surnames as trademark

    • Hold Dr Reddys Laboratories: Ventura Securities

      Ventura Securities has recommended hold rating on Dr Reddy Laboratories (DRL), in its February 21, 2013 research report. The research firm, expects company's performance in FY14 to remain muted and restricted to single digit growth.

    • Kronos Drives Workforce Compliance And Productivity At Dr. Reddy's

      Kronos implements its workforce management solution at Dr. Reddy's Laboratories.

    • Unsure of how biz will shape up in German mkt: Dr Reddy's

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347